Indian firm Ipca Laboratories Ltd., whose formulations manufacturing sites in Silvassa and the Special Economic Zone in Indore and an active pharmaceutical ingredients (APIs) unit in Ratlam had been placed under import alert by the US Food and Drug Administration, has received a temporary breather from the agency for hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials being evaluated as potential treatments for coronavirus. (Also see "Ipca On Tailspin After Three-Plant FDA Ban" - Scrip, 16 June, 2017.)
Ipca informed Indian stock markets that the FDA had indicated it had “made exception” to the enforcement action for the firm’s hydroxychloroquine sulphate and chloroquine phosphate APls manufactured at Ratlam and for hydroxychloroquine sulphate tablets made at the units in SEZ Indore and in Pithampur and Piparia in